Trial Profile
Impact of pre-treatment with ruxolitinib versus transplantation of ruxolitinib-naive myelofibrosis patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Sep 2019
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease; Myelofibrosis
- Focus Therapeutic Use
- 19 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology